Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Observes Tumor Treating Fields use in pleural mesothelioma patients

Collects real-life data on a device treatment in adults with pleural mesothelioma.

Key facts

Who runs it
NovoCure Ltd.
Where
Berlin, Bremen, Cologne, Dresden, Düsseldorf, Essen, Gauting, Georgsmarienhütte, Göttingen, Halle, Hanover, Harburg, Hemer, Herne, Moers, Münster, Regensburg, and Wangen, GermanySee the 20 sitesAlso in 2 other countries, 3 sites
Trial code
Registry title
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study
Status
Recruiting
People taking part
198 people, planned
Started
1 Aug 2023
Expected to end
Jun 2028
Type of study
Observational
Treatments tested
  • TTFields
Record updated
22 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pleural mesothelioma who cannot have surgery to remove the tumour and are planned to get TTFields treatment in routine care.

Age
18 years or older
Sex
All sexes can join
Disease stage
Pleural mesothelioma confirmed by tissue examination, with no option of surgery to remove it fully
Earlier treatment
Treatment with the NovoTTF-200T System is planned. People who already had NovoTTF-200T for more than 1 week at enrolment cannot join.

Main reasons for not taking part

  • Previous treatment with NovoTTF-200T for more than 1 week at enrolment
  • Expected survival of 3 months or less at enrolment
  • No signed informed consent to use and process data

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • ≥ 18 years of age
  • Histologically confirmed pleural mesothelioma without any option of curative resection
  • Planned treatment with NovoTTF-200T System according to IFU and medical guidelines
  • Life expectancy more than 3 months at day of enrollment
  • Signed informed consent for use and processing of data

Who cannot take part

  • Previous treatment with NovoTTF-200T for more than 1 week at day of enrollment

Where in Germany

Also in 2 other countries, 3 sites

  • Charité Universitätsmedizin BerlinBerlin, GermanyContact: Nikolaj FrostTaking people
  • Lungenklinik HeckeshornBerlin, GermanyContact: Daniel MischTaking people
  • Klinikum Bremen-OstBremen, GermanyContact: André BethgeTaking people
  • Kliniken der Stadt KoelnCologne, GermanyContact: Carolin Gross-Ophoff-MüllerTaking people
  • University Hospital Carl Gustav Carus DresdenDresden, GermanyContact: Till PloenesTaking people
  • Florence-Nightingale-HospitalDüsseldorf, GermanyContact: Aris KoryllosTaking people
  • Klinikum Essen-MitteEssen, GermanyContact: Konstantinos FerrentinosTaking people
  • University Hospital EssenEssen, GermanyContact: Martin MetzenmacherTaking people
  • Lungenklinik GautingGauting, GermanyContact: Rudolf A HatzTaking people
  • Niels-Stensen HospitalGeorgsmarienhütte, GermanyContact: Giovanni CeresoliTaking people
  • University Medicine GottingenGöttingen, GermanyContact: Rami El-ShafieTaking people
  • Krankenhaus Martha-Maria Halle-DoelauHalle, GermanyContact: Wolfgang SchuetteTaking people
  • Medizinische Hochschule HannoverHanover, GermanyContact: Heiko GolponTaking people
  • Asklepios Klinikum HarburgHarburg, GermanyContact: Claas WesselerTaking people
  • Lungenklinik HemerHemer, GermanyContact: Karsten SchulmannTaking people
  • Evangelisches Krankenhaus HerneHerne, GermanyContact: Daniel ChristophTaking people
  • Krankenhaus Bethanien MoersMoers, GermanyContact: Kato KambartelTaking people
  • GEHO MuensterMünster, GermanyContact: Rüdiger LierschTaking people
  • University Hospital RegensburgRegensburg, GermanyContact: Michael RiedTaking people
  • Fachkliniken WangenWangen, GermanyContact: Philipp MeynTaking people

About the trial

What the trial wants to find out

The purpose of this post-authorisation medical device study is to obtain real life data on the use of Tumor Treating Fields (TTFields) in patients with pleural mesothelioma in routine clinical care. Patients with pleural mesothelioma and clinical indication for TTFields treatment will be enrolled in the study after signing Informed consent to use their data and process it centrally for research purposes. The clinical indication for TTFields is one of the inclusion criteria and is defined prior to inclusion by the treating physician.

The group in the trial

  • Group 1

    all patients will receive routine clinical care and TTFields

    Treatment: TTFields

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study - TIGER Meso Study
Plain-language title
Observes Tumor Treating Fields use in pleural mesothelioma patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 August 2025